Evolus (EOLS) Free Cash Flow Growth (3y) (2020 - 2026)
Evolus (EOLS) Free Cash Flow Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 9.86% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -18.92% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -44.64% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 0.68% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -27.74% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 46.56% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 39.19% |
| 10 | Evolus | 403.51 Mn | 353.71 Mn | 48.90 Mn | 21.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.77% |
| Dec 31, 2025 | 48.27% |
| Sep 30, 2025 | 3.01% |
| Jun 30, 2025 | -9.04% |
| Mar 31, 2025 | 25.26% |
| Dec 31, 2024 | 36.00% |
| Sep 30, 2024 | 45.05% |
| Jun 30, 2024 | -35.14% |
| Mar 31, 2024 | -9.23% |
| Dec 31, 2023 | 32.05% |
| Sep 30, 2023 | 51.19% |
| Jun 30, 2023 | 3.78% |
| Mar 31, 2023 | 9.54% |
| Dec 31, 2022 | 15.40% |
| Sep 30, 2022 | 11.51% |
| Jun 30, 2022 | 14.04% |
| Mar 31, 2022 | -25.79% |
| Dec 31, 2021 | 10.99% |
| Sep 30, 2021 | -78.47% |
| Jun 30, 2021 | 68.95% |